Source / episode info

• **Episode:**127
• **Title:**Divine Intervention Episode 127 – USMLE Step 2CK Rapid Review Series 8 (OBGYN)
• **Published:**2019-07-25
• Source:Episode page

One-liner

This episode reviews high-yield OBGYN topics including risk factors for Candida and BV; the clinical presentation of genetic anomalies like AIS and Mollerian agenesis; management principles for Benign Prostatic Hyperplasia (BPH); and critical associations in myocarditis etiology and pharmacology.

High-yield summary

• Candida/BV Risk Factors: Increased risk includes diabetes, HIV/immunocompromise, chronic steroid use, recent antibiotic exposure, and smoking.
• Pap Smear Interval Change: In immunocompromised patients (e.g., HIV), the Pap smear interval shortens from every 3 years to annually.
• AIS Phenotype: A patient with AIS will have a 46,XY genotype but may present phenotypically female, lacking a uterus and internal genitalia, but retaining developmentally appropriate breasts and pubic/axillary hair (due to aromatase converting T to E).
• Myocarditis Drugs: Doxorubicin causes irreversible dilated cardiomyopathy; Trastuzumab causes reversible dilated cardiomyopathy. Dexrazoxane is used to prevent anthracycline cardiotoxicity.
• BPH Management: Acute relief requires an _1-blocker (e.g., Tamsulosin); long-term management requires a 5- reductase inhibitor (e.g., Finasteride) to shrink the prostate.
• PDE-5 Inhibitors: These drugs increase cAMP in smooth muscle, causing vasodilation and decreasing systemic vascular resistance (SVR), which can lead to orthostatic hypotension when combined with other vasodilators (like nitrates).

Learning objectives

• Identify risk factors for recurrent vaginal candidiasis and bacterial vaginosis (BV).
• Differentiate the clinical presentation and management of genetic anomalies like AIS and Mollerian agenesis.
• Understand the mechanism and appropriate timing of treatment for BPH symptoms versus prostate enlargement.
• Recognize the key drugs associated with myocarditis, differentiating between reversible and irreversible cardiotoxicity.
• Correlate drug classes (e.g., PDE-5 inhibitors) with cardiovascular side effects (vasodilation/hypotension).